PA
CRSP icon

Profund Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Profund Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Sell
29,083
-11,926
-29% -$629K 0.04% 253
2026
Q1 		$1.95M Buy
41,009
+2,899
+8% +$153K 0.07% 215
2025
Q4 		$2M Buy
38,110
+4,766
+14% +$285K 0.06% 218
2025
Q3 		$2.16M Buy
33,344
+9,081
+37% +$521K 0.07% 180
2025
Q2 		$1.18M Sell
24,263
-4,644
-16% -$180K 0.04% 263
2025
Q1 		$984K Sell
28,907
-1,526
-5% -$64.7K 0.04% 298
2024
Q4 		$1.2M Sell
30,433
-10,064
-25% -$475K 0.04% 267
2024
Q3 		$1.9M Buy
40,497
+8,081
+25% +$410K 0.07% 195
2024
Q2 		$1.75M Buy
32,416
+14,820
+84% +$857K 0.06% 194
2024
Q1 		$1.2M Sell
17,596
-4,355
-20% -$312K 0.05% 310
2023
Q4 		$1.37M Sell
21,951
-7,317
-25% -$404K 0.06% 263
2023
Q3 		$1.33M Buy
29,268
+5,184
+22% +$268K 0.07% 224
2023
Q2 		$1.35M Sell
24,084
-4,525
-16% -$257K 0.07% 241
2023
Q1 		$1.29M Buy
28,609
+19,876
+228% +$965K 0.08% 228
2022
Q4 		$355K Buy
8,733
+227
+3% +$12K 0.02% 555
2022
Q3 		$556K Buy
8,506
+364
+4% +$26.4K 0.04% 360
2022
Q2 		$495K Sell
8,142
-629
-7% -$37K 0.03% 414
2022
Q1 		$551K Buy
+8,771
New +$551K 0.02% 511

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Profund Advisors's CRSP Position: Q2 2026 in Review

Profund Advisors reduced its CRISPR Therapeutics (CRSP) stake by 29% in Q2 2026, selling an estimated $629K and leaving 29,083 shares worth $1.59M. The position accounts for 0.04% of the portfolio, ranked #253.

Profund Advisors first reported a position in CRSP in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.16M in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Profund Advisors held 29,083 shares of CRISPR Therapeutics worth $1.59M as of Q2 2026.
  • Profund Advisors sold 11,926 CRISPR Therapeutics shares in Q2 2026, an estimated $629K.
  • CRISPR Therapeutics made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #253 holding.
  • Profund Advisors first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Profund Advisors's CRISPR Therapeutics position peaked at $2.16M in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.